EP0850067A4 - Verfahren zur krebsbehandlung unter verwendung von 6-(3-(1-adamantyl)-4-hydroxyphenyl)2 naphtalincarbonsäure - Google Patents

Verfahren zur krebsbehandlung unter verwendung von 6-(3-(1-adamantyl)-4-hydroxyphenyl)2 naphtalincarbonsäure

Info

Publication number
EP0850067A4
EP0850067A4 EP96924519A EP96924519A EP0850067A4 EP 0850067 A4 EP0850067 A4 EP 0850067A4 EP 96924519 A EP96924519 A EP 96924519A EP 96924519 A EP96924519 A EP 96924519A EP 0850067 A4 EP0850067 A4 EP 0850067A4
Authority
EP
European Patent Office
Prior art keywords
adamantyl
hydroxyphenyl
treating cancers
cancers
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96924519A
Other languages
English (en)
French (fr)
Other versions
EP0850067A1 (de
Inventor
Joseph A Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Centre International de Recherches Dermatologiques Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre International de Recherches Dermatologiques Galderma filed Critical Centre International de Recherches Dermatologiques Galderma
Publication of EP0850067A1 publication Critical patent/EP0850067A1/de
Publication of EP0850067A4 publication Critical patent/EP0850067A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP96924519A 1995-07-17 1996-07-17 Verfahren zur krebsbehandlung unter verwendung von 6-(3-(1-adamantyl)-4-hydroxyphenyl)2 naphtalincarbonsäure Ceased EP0850067A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US601465 1990-10-23
US146595P 1995-07-17 1995-07-17
PCT/US1996/011736 WO1997003682A1 (en) 1995-07-17 1996-07-17 Method for treating cancers using 6-[3-[1-adamantyl]-4-hydroxyphenyl]

Publications (2)

Publication Number Publication Date
EP0850067A1 EP0850067A1 (de) 1998-07-01
EP0850067A4 true EP0850067A4 (de) 1999-12-15

Family

ID=21696159

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96924519A Ceased EP0850067A4 (de) 1995-07-17 1996-07-17 Verfahren zur krebsbehandlung unter verwendung von 6-(3-(1-adamantyl)-4-hydroxyphenyl)2 naphtalincarbonsäure

Country Status (5)

Country Link
EP (1) EP0850067A4 (de)
JP (1) JP2000506489A (de)
AU (1) AU701790B2 (de)
CA (1) CA2223489A1 (de)
WO (1) WO1997003682A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739557B1 (fr) 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
RU2209626C2 (ru) * 1996-07-08 2003-08-10 Галдерма Ресерч энд Девелопмент, С.Н.С. Производные адамантила, вызывающие апоптоз, и их использование в качестве противораковых агентов
US6462064B1 (en) 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
CA2383347A1 (en) 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
BR0207846A (pt) 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
AU2002352706A1 (en) 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
EP1567172A2 (de) * 2002-11-29 2005-08-31 GPC Biotech AG Zubereitungen zur behandlung von hepatitis c infektion
WO2007108272A1 (ja) * 2006-03-23 2007-09-27 Tmrc Co., Ltd. 癌治療用キットおよび癌治療用医薬組成物
WO2007148804A1 (ja) * 2006-06-23 2007-12-27 Rohto Pharmaceutical Co., Ltd. ヒアルロン酸産生促進能を有する組成物
EP3301085A1 (de) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoidderivate mit antitumorwirkung
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85849A1 (fr) * 1985-04-11 1986-11-05 Cird Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOEHM M F ET AL: "DESIGN AND SYNTHESIS OF POTENT RETINOID X RECEPTOR SELECTIVE LIGANDS THAT INDUCE APOPTOSIS IN LEUKEMIA CELLS", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 16, 4 August 1995 (1995-08-04), pages 3146 - 3155, XP000615461, ISSN: 0022-2623 *
CORBEIL J ET AL: "ANTIPROLIFERATIVE EFFECT OF RETINOID COMPOUNDS ON KAPOSI'S SARCOMA CELLS", JOURNAL OF CLINICAL INVESTIGATION, vol. 93, no. 5, 1 May 1994 (1994-05-01), pages 1981 - 1986, XP000646558, ISSN: 0021-9738 *
SCHADENDORF, D. ET AL.: "Retinoic acid receptor-gamma-selective retinoids exert antiproliverative effects on human melanoma cell growth in vitro", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 5, no. 6, 1994, pages 1325 - 1331, XP000600684 *
See also references of WO9703682A1 *
SHAO Z -M ET AL: "P53 INDEPENDENT G0/G1 ARREST AND APOPTOSIS INDUCED BY A NOVEL RETINOID IN HUMAN BREAST CANCER CELLS", ONCOGENE, vol. 11, no. 3, 3 August 1995 (1995-08-03), pages 493 - 504, XP000575582, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
EP0850067A1 (de) 1998-07-01
WO1997003682A1 (en) 1997-02-06
JP2000506489A (ja) 2000-05-30
AU6494996A (en) 1997-02-18
AU701790B2 (en) 1999-02-04
CA2223489A1 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
IL116242A (en) Irradiation apparatus
PL323178A1 (en) Schirophrenia diagnosin method
EP0850067A4 (de) Verfahren zur krebsbehandlung unter verwendung von 6-(3-(1-adamantyl)-4-hydroxyphenyl)2 naphtalincarbonsäure
IL125031A0 (en) Method for treating depression
GB9518442D0 (en) Method
GB9519638D0 (en) Method
GB2308522B (en) Redialling method
IL124786A0 (en) Method for treating pain
GB9502225D0 (en) Method
GB9510727D0 (en) Method
ZA971899B (en) Method for treating insomnia
AP9701121A0 (en) Method for prearing streptogramines
GB9511828D0 (en) Method
GB9722553D0 (en) Method
GB2296850B (en) Apparatus for applying designs
AU2198997A (en) Method for treating insomnia
GB9505895D0 (en) Apparatus for treating shoes
GB9511594D0 (en) Treatment method
GB9513129D0 (en) Treatment method
GB9513130D0 (en) Treatment method
HU9400631D0 (en) Process for treating tumors
GB9508498D0 (en) Dying method
GB9516974D0 (en) Method
GB9526269D0 (en) Method
GB9519145D0 (en) Method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991104

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20001005

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/79 A, 7A 61P 35/02 B, 7A 61P 35/00 B

RTI1 Title (correction)

Free format text: METHOD FOR TREATING BREAST CANCER AND LEUKEMIA USING 6- (3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-2-NAPHTHALENE CARBOXYLIC ACID

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/79 A, 7A 61P 35/02 B, 7A 61P 35/00 B

RTI1 Title (correction)

Free format text: 6- (3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-2-NAPHTHALENE CARBOXYLIC ACID AGAINST BREAST CANCER AND LEUKEMIA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/79 A, 7A 61P 35/02 B, 7A 61P 35/00 B

RTI1 Title (correction)

Free format text: 6- (3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-2-NAPHTHALENE CARBOXYLIC ACID AGAINST BREAST CANCER AND LEUKEMIA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020429

RTI1 Title (correction)

Free format text: 6- ??3-??1-ADAMANTYL -4-HYDROXYPHENYL -2-NAPHTHALENE CARBOXYLIC ACID AGAINST BREAST CANCER AND LEUKEMIA